Cardiocel Revenue and Company Growth, page-122

Haven't been watching closely but the low of 42 constituted 16,222 shares traded in 2 parcels, quite a bit below the adjacent trades, with couple of moderate sized trades before.

I don't feel too disappointed, although I'm a fair way in the red. The only changes to the company's status are that they have sold more products, used some more cash and progressed further along with the trials. There is no disaster/adverse event to justify a 30% fall in price. If you believe in the company and would like more, maybe a good time to take advantage, or just sit tight, most likely all will be well in a few months.